Please login to the form below

Not currently logged in

COVID-19 delays Pfizer, Mylan’s generics merger and spin-out

Fallout from pandemic continues to affect business in myriad ways


The fallout from the COVID-19 pandemic is affecting business in myriad ways, and that includes regulatory reviews of mergers and acquisitions.

The merger between Pfizer’s Upjohn generics unit and Mylan is thought to be the first big transaction in pharma to be set back as a result of the widespread disruption caused by the coronavirus, and is now scheduled to take place in the latter half of this year.

Meanwhile, Mylan's meeting of shareholders to approve the deal is also being moved back from 27 April to 30 June. It’s due to be held in the Netherlands, where Mylan is domiciled, and for now the country has a ban on meetings.

Pfizer’s plan to spin out its Upjohn generic drugs business into a joint venture with Mylan called Viatris was formerly due to complete in the middle of this year. It will create a generics giant with annual sales of around $20bn this year, owned 57% to 43% by Pfizer and Mylan shareholders, respectively.

It is part of a restructuring drive at the big pharma company that aims to slim down its operations, concentrate resources on its more-profitable branded medicines division, and provide it with extra capital to spend on bolt-on acquisitions and licensing.

Pfizer has also previously shed its veterinary business, a baby formula unit and its consumer products division via a deal with GlaxoSmithKline.

There are no changes to the terms of the deal, which will see Pfizer acquire Mylan, merge it with Upjohn and spin out the combined division as a separate company. The delay is simply put down to “unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process”.

The Federal Trade Commission (FTC) and Department of Justice (DoJ) said this week that they were implementing an expedited antitrust procedure to make it easier for companies to work together on COVID-19 related activities such as temporarily combining production, distribution, or service networks.

At the same time, it has warned that some antitrust reviews may take longer, for example if key staff and documents can’t be made available during the crisis.

“Mylan, Pfizer and Upjohn are working closely on integration planning and are making significant progress toward Day 1 readiness,” they said in a joint statement. “Together the companies continue to progress toward a successful close.”

Article by
Phil Taylor

27th March 2020

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
6 critical success factors for flawless execution of a rapid first commercial launch
Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline....
Hybrid working: Insights and tips for success
Porterhouse Medical has thrived by embracing a hybrid approach to work. Our article looks at hybrid working and provides some tips for success...